Arcalyst (rilonacept) Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Arcalyst (rilonacept) market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The growth observed in the historic period can be attributed to increased awareness of autoimmune diseases, a higher incidence of cryopyrin-associated periodic syndromes (CAPS), the growing presence of specialty pharmacies, greater awareness of rare diseases, and an increase in clinical trials and studies involving rilonacept.

The growth projected for the forecast period is driven by the rising demand for injectable biologics, increasing healthcare expenditure, a growing global patient population, a higher demand for treatments for inflammatory diseases, and an increasing interest in personalized medicine. Key trends in the forecast period include advancements in biologic therapies for autoimmune conditions, collaborations between pharmaceutical companies, progress in precision medicine and targeted therapies, technological innovations, and improvements in drug delivery systems.

The growing demand for personalized medicines is expected to drive the growth of the arcalyst (rilonacept) market going forward. Personalized medicine tailors treatment and healthcare decisions to an individual’s characteristics, including genetics, environment, and lifestyle. The demand for personalized medicine is rising due to its potential to improve treatment effectiveness, reduce adverse effects, and address individual variability in disease progression and drug response. As personalized medicine becomes more common, there is greater awareness and better diagnostic tools to identify rare, genetically driven conditions, which results in an increase in diagnoses that Arcalyst can treat. For instance, in February 2024, the Personalized Medicine Coalition (PMC) reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, compared to just 6 in 2022. Additionally, in February 2023, PMC reported that 12 new personalized medicines were approved by the FDA in 2022, marking the eighth consecutive year where personalized medicines comprised at least a quarter of all new drug approvals. Therefore, the growing demand for personalized medicines is driving the growth of the arcalyst (rilonacept) market.

A key trend in the arcalyst (rilonacept) market is adopting a strategic partnership approach to develop and commercialize Arcalyst with enhanced technology integration and to expand market reach. Strategic partnerships enable companies to leverage each other's strengths and resources to achieve mutual success. For instance, in February 2022, Kiniksa Pharmaceuticals Ltd., a Bermuda-based biopharmaceutical company, partnered with Huadong Medicine Co. Ltd., a China-based pharmaceutical company, to develop and commercialize Arcalyst and mavrilimumab in the Asia-Pacific region. Under this agreement, Kiniksa received an upfront payment of $22 million and could earn up to $640 million through milestone payments based on development, regulatory approvals, and sales. Huadong Medicine holds exclusive rights for the development and commercialization of Arcalyst in Greater China, South Korea, Australia, and 18 other countries, excluding Japan.

In August 2023, Fairmount Funds Management LLC, a South Philadelphia-based investment firm, acquired a stake in Kiniksa Pharmaceuticals for an undisclosed amount. This strategic move is part of Fairmount's broader investment strategy aimed at long-term value generation within the biotechnology sector. Kiniksa Pharmaceuticals is the manufacturer of Arcalyst (rilonacept).

Major players operating in the arcalyst (rilonacept) market are Regeneron Pharmaceuticals Inc., Kiniksa Pharmaceuticals Ltd.

North America was the largest region in the arcalyst (rilonacept) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in arcalyst (rilonacept) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the arcalyst (rilonacept) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Arcalyst (rilonacept) is a prescription medication classified as an interleukin-1 (IL-1) blocker. It is used to treat inflammatory conditions caused by the overproduction of interleukin-1, a protein that plays a key role in the body’s inflammatory response. Rilonacept works by binding to interleukin-1 alpha and beta, preventing their interaction with specific receptors, thus reducing inflammation and alleviating symptoms related to these conditions.

The primary formulations of arcalyst (rilonacept) include lyophilized and liquid forms. The lyophilized version is a freeze-dried formulation designed for reconstitution prior to administration. Arcalyst is indicated for conditions such as cryopyrin-associated periodic syndromes (CAPS), deficiency of interleukin-1 receptor antagonist (DIRA), and other indications. It is distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies, and is used by both adult and pediatric patients.

The arcalyst (rilonacept) market research report is one of a series of new reports that provides arcalyst (rilonacept) market statistics, including arcalyst (rilonacept) industry global market size, regional shares, competitors with a arcalyst (rilonacept) market share, detailed arcalyst (rilonacept) market segments, market trends and opportunities, and any further data you may need to thrive in the arcalyst (rilonacept) industry. This arcalyst (rilonacept) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The arcalyst (rilonacept) market consists of monoclonal antibodies, anti-inflammatory drugs, rare disease drugs and other related products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.